Male sex independently associated with greater mSASSS increase (β 0.29), higher odds of ≥2-unit mSASSS progression (OR 2.08), and new syndesmophyte formation (OR 1.90) in #axSpA despite lower disease activity scores. Treat symptoms and progression Abstr OP0101 @RheumNow

RD in #IBD: 18.6% of 650 IBD pts affected, most commonly peripheral arthritis and AxSpa. Key finding: 14% of rheumatic manifestations preceded IBD diagnosis. Rheumatologists may see these pts first. GI-rheum collaboration is essential. @RheumNow #EULAR2026 POS0807 https://t.co/028yzOxJ2R

• https://x.com/JihaRheum/status/2062531819187085434/photo/1

#EULAR2026 POS0079 Phase I study of “Off-the-Shelf” CD19 CAR-T FT819 in N=13 #SLE pts with/-out LN reported favourable efficacy and safety particularly with Bendamustine conditioning. Advantages: scalable and requires minimal or no conditioning. Will move on to Phase II @RheumNow https://t.co/2rt646Qf0T

• https://x.com/Yuz6Yusof/status/2062529425246240921/photo/1

Over 10 years in the GESPIC cohort, males with #axSpA had lower ASDAS/BASDAI and enthesitis but double the odds of significant spinal radiographic progression vs females (OR 2.08). Symptoms don’t always correlate to structural damage Abstr OP0101 @RheumNow #EULAR2026

After TNFi secondary failure: does MOA switch beat TNFi cycling? UK RWD (n=155): yes for #PsA (76% vs 57% drug survival at 12m) and axSpA (80% vs 68%), but not RA. Yet 74% of axSpA pts still got another TNFi. Evidence vs practice gap in plain sight. @RheumNow #EULAR2026 POS0776

JAKi vs ABA in RA-ILD: emulated target trial (n=1,162), JAKi with worse composite respiratory outcomes (HR 1.57) and all-cause mortality (HR 1.59) vs ABA over 5 yrs. JAKi with ↑ pneumonia risk. In RA-ILD, ABA may be the preferred choice? @RheumNow #EULAR2026 POS0813 #EULARBEST

Real-world bimekizumab in SpA/#PsA (BIMPACT, n=223): 76% retention at 12mo, even with 54% having prior IL-17i exposure. Effective after IL-17Ai failure. Oral candidiasis higher in PsA (16.5%) vs SpA (3.3%); led to discontinuation in ~25%. @RheumNow #EULAR2026 POS0798/POS0810

What defines MRI indicative of axSpA? This systematic lit review show adapting more stringent cutoffs in BME (>=4 SIJ quads, erosion >=3 quads, fat >=5 SIJ quads) & combined BME + structural lesions inc specificity. Time for updated definitions? AbsPOS0866 @RheumNow #EULAR2026 https://t.co/gkVbcOAiD3

• https://x.com/RHEUMarampa/status/2062515092722208958/photo/1

ClearMEMory: Ph2 RCT evaluating memantine for tx of cognitive impairment in SLE using RBANS as outcome measure MEM grp had sig. higher change in RBANS TIScore upto wk 12 vs. PBO, esp. immediate memory index score Potential adjunct tx for NPSLE? AbsPOS0701 @RheumNow #EULAR2026 https://t.co/UffdVPRu6s

• https://x.com/RHEUMarampa/status/2062506356192538724/photo/1

@RheumNow WIN Nutrition session #EULAR2026 (4) 🌾 Gluten does NOT influence biologic response in RD, BELIEVE cohort, 197 pts. No need to go gluten-free unless celiac disease 🌱 Plants for Joints trial: plant-based diet + exercise → sustained DAS28&WOMAC improvement @ 2Y, RA/OA @RheumNow

@RheumNow WIN Nutrition session at #EULAR2026 (3) 6.🍟 High UPF intake → increased RA risk (HR 1.06/SD), partly mediated by CRP. Not all NOVA-4 foods are equal 7.💊 Vit D supplementation significantly reduces SLE disease activity — MA of 10 RCTs, SMD −0.54 (p<0.00001). @RheumNow

WIN Nutrition session at #EULAR2026 (2) 🐟 n-3 PUFAs reduce RA risk by 9–10% per SD increase — especially in genetically high-risk individuals. 🫒 Mediterranean diet reduces RA risk by 25% (HR 0.75) & SLE risk by 39% (HR 0.61) in UK Biobank studies. @RheumNow

WIN Nutrition session at #EULAR2026 (1) 🫐Higher fruit intake → RR 0.88 & cereal intake → RR 0.87 for RA onset 🥩 Highest quartile of red & processed meat intake → nearly DOUBLE the risk of RA onset (OR 1.92, CI 1.11–3.35) @rheumnow https://t.co/RhO08FXtLI

• https://x.com/Nellziade/status/2062496633867165972/photo/1

COMPARE Ph I trial CD19 CAR T-cell ACPA+ refractory RA 6 pts median 6.5 b/tsDMARDs Single CAR T infusion after lymphodepletion Safety -CRS only grade 1–2 (no severe events) -No ICANS -Transient neutropenia -No unexpected toxicities Efficacy DAS28-CRP ↓ ~41% median 50% achieved https://t.co/cdEfGKcJUp

• https://x.com/AurelieRheumo/status/2062491277191438681/photo/1

D2T RA shows a linked brain–psychology–immune signature Cohort D2T RA vs non-D2T RA vs HC 91% D2T RA Higher catastrophizing Higher pain sensitivity More emotion-focused coping strategies “Chronic pain-like” profile Associated with higher CNS related gene expression NRG1 https://t.co/nkQco73vqI

• https://x.com/AurelieRheumo/status/2062489005208334506/photo/1